Elanco Animal Health Inc. — Q2 2019 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2019. The company completed its separation from Eli Lilly on March 11, 2019; 2018 comparative results are combined historical statements, so periods are not fully comparable. Amounts are in millions except per-share data.
Financial performance
| Metric | Q2 2019 | Q2 2018 | Six months 2019 | Six months 2018 |
|---|---|---|---|---|
| Revenue | $781.6 | $770.2 | $1,512.7 | $1,506.4 |
| Gross profit / gross margin | $425.6 / 54.4% | $338.7 / 44.0% | $812.9 / 53.7% | $714.9 / 47.5% |
| Income (loss) before tax | $50.2 | $(40.0) | $95.0 | $37.5 |
| Net income (loss) | $35.9 | $(62.8) | $67.4 | $9.9 |
| Diluted EPS | $0.10 | $(0.21) | $0.18 | $0.03 |
| Operating cash flow | Not separately provided | Not separately provided | $58.2 | $183.9 |
| Capital expenditures | Not separately provided | Not separately provided | $51.8 | $56.5 |
Q2 revenue rose 1%; six-month revenue was nearly flat. Q2 revenue benefited from volume and pricing, partly offset by 3% unfavorable foreign exchange. Gross margin improved substantially, reflecting manufacturing productivity gains and the prior-year inventory and facility charges. Q2 special charges were $31.8 versus $68.0; six-month charges were $56.7 versus $70.4. Interest expense was $20.7 for Q2 and $41.5 for the first half, compared with none in the prior-year periods.
Revenue trends and material changes
- Q2 category revenue: Companion Animal Disease Prevention $223.4 (+4%); Companion Animal Therapeutics $83.4 (+22%); Food Animal Future Protein & Health $175.8 (+2%); Food Animal Ruminants & Swine $271.5 (−9%); Strategic Exits $27.5.
- Companion Animal Therapeutics growth was led by Galliprant. Ruminants & Swine declined amid African Swine Fever-related softness in Asia, antimicrobial policies, product rationalizations, unfavorable Rumensin purchasing patterns, and a contract-manufacturer supply disruption.
- Q2 U.S. revenue was $395.0 versus $366.4; international revenue was $386.6 versus $403.8. Foreign exchange reduced Q2 revenue by $23.0 and first-half revenue by $44.2.
- R&D increased to $68.8 in Q2 (+12%); marketing, selling and administrative expense increased to $200.9 (+5%), including product promotion and standalone-company costs.
Cash, debt and liquidity
- At June 30, cash and cash equivalents were $385.1; restricted cash was $11.5. Current assets were $2,383.5 and current liabilities $777.5.
- Total debt was $2,409.1, including $2,382.0 long-term debt; debt declined from $2,472.3 at year-end. Debt included $2.0 billion of senior notes and a $427.5 term facility. The company repaid $65.0 of borrowings during the first half.
- First-half operating cash flow fell to $58.2 from $183.9, primarily because of increases in receivables, inventory and other assets. Investing cash outflow was $77.5; financing cash outflow was $249.8, including separation-related payments. Cash, cash equivalents and restricted cash declined $280.9 to $396.6.
- Management said available cash, operating cash flow and financing arrangements should support needs for the foreseeable future, including at least the next 12 months. A $750 million revolving credit facility was also established in connection with the separation.
Outlook, risks and unusual items
- No specific revenue or earnings guidance is provided in the supplied filing text. Management estimated annual interest expense of approximately $85 million and standalone “stand up” costs of $240–$290 million, net of potential real estate dispositions; some costs will be capitalized.
- Elanco completed the Aratana acquisition on July 18, 2019, issuing approximately 7.3 million shares valued at $241.6 million, with a contingent payment of up to approximately $12 million. It acquired Prevtec on July 31 for approximately CAD $78.5 million, with potential additional milestone payments of up to CAD $21.5 million. Acquisition accounting was incomplete at filing.
- Key disclosed risks include generic competition, regulatory restrictions on food-animal antibiotics, product safety or efficacy issues, R&D and acquisition execution, foreign-exchange exposure, emerging-market conditions, Brexit-related uncertainty, and transition costs and operational complexity following separation. A hypothetical 10% adverse currency move was estimated to reduce first-half net income by approximately $5.3 million; the CHF net-investment hedge carries potential 2023 settlement exposure.
- One customer represented 12.5% of Q2 revenue. The filing reports no significant probable and estimable litigation liabilities. Disclosure controls were deemed effective.
Important facts for investors to verify
- Whether improved gross margins and productivity gains persist after adjusting for prior-year charges and product mix.
- Whether cash conversion recovers as receivables, inventory and other operating assets absorb less cash.
- The trajectory of Ruminants & Swine revenue, including impacts from African Swine Fever, generic competition and supply constraints.
- Actual remaining separation and standalone costs versus the $240–$290 million estimate, and the timing of resulting savings.
- Integration costs, financing needs and purchase-accounting outcomes for the Aratana and Prevtec acquisitions.